{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:19:50Z","timestamp":1781104790849,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40256-022-00549-2","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T09:02:36Z","timestamp":1663837356000},"page":"695-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Haemodynamic Effects of Sacubitril\/Valsartan Initiation in Outpatients with Chronic Heart Failure"],"prefix":"10.1007","volume":"22","author":[{"given":"Hanna","family":"Fr\u00f6hlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Estler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"M\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Frankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"T\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"11","key":"549_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"key":"549_CR2","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1002\/ehf2.12974","volume":"7","author":"H Zhang","year":"2020","unstructured":"Zhang H, Huang T, Shen W, Xu X, Yang P, Zhu D, et al. Efficacy and safety of sacubitril\u2013valsartan in heart failure: a meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7:3841\u201350.","journal-title":"ESC Heart Fail."},{"issue":"331","key":"549_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","volume":"15","author":"C Proudfoot","year":"2021","unstructured":"Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S, et al. Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review. Int J Cardiol. 2021;15(331):164\u201371.","journal-title":"Int J Cardiol"},{"issue":"5","key":"549_CR4","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1002\/ehf2.13547","volume":"8","author":"S Giovinazzo","year":"2021","unstructured":"Giovinazzo S, Carmisciano L, Toma M, Benenati S, Tomasoni D, Sormani MP, et al. Sacubitril\/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(5):3547\u201356.","journal-title":"ESC Heart Fail."},{"issue":"11","key":"549_CR5","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril\u2013svalsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322(11):1085\u201395.","journal-title":"JAMA"},{"key":"549_CR6","doi-asserted-by":"crossref","unstructured":"Abumayyaleh M, Demmer J, Krack C, Pilsinger C, El-Battrawy I, Behnes M, et al. Hemodynamic effects of sacubitril\/valsartan in patients with reduced left ventricular ejection fraction over 24 months: a retrospective study. Am J Cardiovasc Drugs. 2022;22(5):535\u201344.","DOI":"10.1007\/s40256-022-00525-w"},{"issue":"4","key":"549_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2217\/fca-2020-0002","volume":"16","author":"M Abumayyaleh","year":"2020","unstructured":"Abumayyaleh M, El-Battrawy I, Behnes M, Borggrefe M, Akin I. Current evidence of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction. Future Cardiol. 2020;16(4):227\u201336.","journal-title":"Future Cardiol"},{"issue":"1","key":"549_CR8","first-page":"63","volume":"15","author":"P Sobanski","year":"2008","unstructured":"Sobanski P, Sinkiewicz W, Kubica J, Blazejewski J, Bujak R. The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure. Cardiol J. 2008;15(1):63\u201370.","journal-title":"Cardiol J"},{"issue":"11","key":"549_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s001340050469","volume":"23","author":"T Koobi","year":"1997","unstructured":"Koobi T, Kaukinen S, Ahola T, Turjanmaa VM. Non-invasive measurement of cardiac output: whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods. Intensive Care Med. 1997;23(11):1132\u20137.","journal-title":"Intensive Care Med"},{"issue":"27","key":"549_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"4","key":"549_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000232407","volume":"114","author":"J Saur","year":"2009","unstructured":"Saur J, Fluechter S, Trinkmann F, Papavassiliu T, Schoenberg S, Weissmann J, et al. Noninvasive determination of cardiac output by the inert-gas-rebreathing method\u2014comparison with cardiovascular magnetic resonance imaging. Cardiology. 2009;114(4):247\u201354.","journal-title":"Cardiology"},{"issue":"5","key":"549_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1751-7133.2003.tb00021.x","volume":"9","author":"C Yancy","year":"2003","unstructured":"Yancy C, Abraham WT. Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography. Congest Heart Failure. 2003;9(5):241\u201350.","journal-title":"Congest Heart Failure."},{"issue":"11","key":"549_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1471-2288-11-175","volume":"28","author":"ES Wong","year":"2011","unstructured":"Wong ES, Wang BC, Garrison LP, Alfonso-Cristancho R, Flum DR, Arterburn DE, et al. Examining the BMI-mortality relationship using fractional polynomials. BMC Med Res Methodol. 2011;28(11):175.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"549_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/00015385.2018.1521054","volume":"74","author":"CW Lau","year":"2019","unstructured":"Lau CW, Martens P, Lambeets S, Dupont M, Mullens W. Effects of sacubitril\/valsartan on functional status and exercise capacity in real-world patients. Acta Cardiol. 2019;74(5):405\u201312.","journal-title":"Acta Cardiol"},{"issue":"3","key":"549_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10557-019-06858-0","volume":"33","author":"C Moliner-Abos","year":"2019","unstructured":"Moliner-Abos C, Rivas-Lasarte M, Pamies Besora J, Fluvia-Brugues P, Sole-Gonzalez E, Mirabet S, et al. Sacubitril\/valsartan in real-life practice: experience in patients with advanced heart failure and systematic review. Cardiovasc Drugs Ther. 2019;33(3):307\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"549_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5543\/tkda.2021.63099","volume":"49","author":"B Ekici","year":"2021","unstructured":"Ekici B, Yaman M, Kucuk M, Dereli S, Yenercag M, Yigit Z, et al. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Turkey (ARNi-TR). Turk Kardiyol Dern Ars. 2021;49(5):357\u201367.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"sup1","key":"549_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/03007995.2019.1576481","volume":"35","author":"ER Cosentino","year":"2019","unstructured":"Cosentino ER, Degli Esposti D, Miceli R, Bentivenga C, Landolfo M, Fg Cicero A, et al. Sacubitril\/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. Curr Med Res Opin. 2019;35(sup1):9\u201312.","journal-title":"Curr Med Res Opin"},{"issue":"sup3","key":"549_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/03007995.2019.1598702","volume":"35","author":"NR Pugliese","year":"2019","unstructured":"Pugliese NR, Fabiani I, Zywicki V, Mazzola M, D\u2019Agostino A, Galeotti GG, et al. Effects of sacubitril\/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction <\/=35. Curr Med Res Opin. 2019;35(sup3):13\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"549_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2217\/cer-2019-0014","volume":"8","author":"H Morillas-Climent","year":"2019","unstructured":"Morillas-Climent H, Seller-Moya J, Vicedo-Lopez A, Galcera-Jornet E, Alania-Torres E, Rodriguez-Pichardo Y, et al. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril\/valsartan initiation in daily practice. J Comp Eff Res. 2019;8(9):685\u201397.","journal-title":"J Comp Eff Res."},{"issue":"2","key":"549_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","volume":"73","author":"L Vicent","year":"2019","unstructured":"Vicent L, Esteban-Fernandez A, Gomez-Bueno M, De-Juan J, Diez-Villanueva P, Iniesta AM, et al. Sacubitril\/valsartan in daily clinical practice: data from a prospective registry. J Cardiovasc Pharmacol. 2019;73(2):118\u201324.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"549_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","volume":"15","author":"C de Diego","year":"2018","unstructured":"de Diego C, Gonzalez-Torres L, Nunez JM, Centurion Inda R, Martin-Langerwerf DA, Sangio AD, et al. Effects of angiotensin\u2013neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018;15(3):395\u2013402.","journal-title":"Heart Rhythm"},{"key":"549_CR22","unstructured":"Gonzalez-Torres L, De Diego C, Centurion R, et al. Angiotensin-neprilysin inhibition further reverses cardiac remodeling as compared to angiotensin inhibition in reduced heart failure patients. Clin Cardiol J. 2018;2(1):6\u20139."},{"key":"549_CR23","first-page":"81","volume":"20","author":"V Goh","year":"2018","unstructured":"Goh V, Koh N, Teoh C, Hon J, Teo L, Lim C, et al. ARNI use leads to improved NYHA class and NT-proBNP levels in a Singaporean cohort. Eur J Heart Fail. 2018;20:81.","journal-title":"Eur J Heart Fail"},{"issue":"8, Supplement","key":"549_CR24","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.cardfail.2019.07.167","volume":"25","author":"C Meloche","year":"2019","unstructured":"Meloche C, Pandrangi P, Parker J, Maley M, Twydell B, Mueller S, et al. The use of sacubitril\/valsartan in an advanced heart failure clinic is associated with decreased heart failure hospitalizations, improved left ventricular ejection fraction and functional class. J Card Fail. 2019;25(8, Supplement):S59.","journal-title":"J Card Fail"},{"key":"549_CR25","first-page":"228","volume":"21","author":"JPR Agostinho","year":"2019","unstructured":"Agostinho JPR, Rodrigues T, Santos R, Cunha N, Rigueira J, Nunes-Ferreira A. Prescription of sacubitril\/valsartan in a real-world population. Eur J Heart Fail. 2019;21:228\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"549_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ehf2.12258","volume":"5","author":"P Martens","year":"2018","unstructured":"Martens P, Beli\u00ebn H, Dupont M, Mullens W. Insights into implementation of sacubitril\/valsartan into clinical practice. ESC Heart Fail. 2018;5(3):275\u201383.","journal-title":"ESC Heart Fail."},{"key":"549_CR27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ejhf.695","volume":"19","author":"A Canu","year":"2017","unstructured":"Canu A, Maurin V, Dos Santos P, Picard F. Results of a single center experience on 200 consecutive patients treated with Entresto (sacubitril\/valsartan). Eur J Heart Fail. 2017;19:413\u20134.","journal-title":"Eur J Heart Fail"},{"key":"549_CR28","first-page":"232","volume":"19","author":"NN Koh","year":"2017","unstructured":"Koh NN, Goh V, Teoh C, Teo L, Lim C, Sim D. Tolerability and short-term outcomes of angiotensin receptor-neprilysin inhibitor (ARNI) use in a Singaporean cohort. Eur J Heart Fail. 2017;19:232.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"549_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","volume":"73","author":"PL Myhre","year":"2019","unstructured":"Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73(11):1264\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"549_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","volume":"85","author":"H Tsutsui","year":"2021","unstructured":"Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction\u2014results from the PARALLEL-HF study. Circ J. 2021;85(5):584\u201394.","journal-title":"Circ J"},{"issue":"1","key":"549_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ehf2.12547","volume":"7","author":"RB Pharithi","year":"2020","unstructured":"Pharithi RB, Ferre-Vallverdu M, Maisel AS, O\u2019Connell E, Walshe M, Sweeney C, et al. Sacubitril\u2013valsartan in a routine community population: attention to volume status critical to achieving target dose. ESC Heart Fail. 2020;7(1):159\u201367.","journal-title":"ESC Heart Fail."},{"key":"549_CR32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ejhf.1354","volume":"21","author":"M Galvan Ruiz","year":"2019","unstructured":"Galvan Ruiz M, Sanmamed Giron M, Singh M, Groba Marco M, Garcia Salvador J, Caballero Dorta E. Use of sacubitril\u2013valsartan in elderly patients. Subanalysis of the SAVE-RLife study. Eur J Heart Fail. 2019;21:238.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"549_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/00325481.2018.1442090","volume":"130","author":"R Wachter","year":"2018","unstructured":"Wachter R, Viriato D, Klebs S, Grunow SS, Schindler M, Engelhard J, et al. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril\/valsartan in Germany. Postgrad Med. 2018;130(3):308\u201316.","journal-title":"Postgrad Med"},{"issue":"6","key":"549_CR34","first-page":"108","volume":"7","author":"A Almufleh","year":"2017","unstructured":"Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, et al. Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis. 2017;7(6):108\u201313.","journal-title":"Am J Cardiovasc Dis"},{"key":"549_CR35","volume":"25","author":"G Bayard","year":"2019","unstructured":"Bayard G, Da Costa A, Pierrard R, Romeyer-Bouchard C, Guichard JB, Isaaz K. Impact of sacubitril\/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. Int J Cardiol Heart Vasc. 2019;25: 100418.","journal-title":"Int J Cardiol Heart Vasc."},{"issue":"4","key":"549_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9040906","volume":"9","author":"M Castrichini","year":"2020","unstructured":"Castrichini M, Manca P, Nuzzi V, Barbati G, De Luca A, Korcova R, et al. Sacubitril\/valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction: standard and advanced echocardiographic evidences. J Clin Med. 2020;9(4):1\u201313.","journal-title":"J Clin Med"},{"key":"549_CR37","volume":"31","author":"M Landolfo","year":"2020","unstructured":"Landolfo M, Piani F, Esposti DD, Cosentino E, Bacchelli S, Dormi A, et al. Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction. Int J Cardiol Heart Vasc. 2020;31: 100656.","journal-title":"Int J Cardiol Heart Vasc."},{"issue":"5","key":"549_CR38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.21037\/cdt-21-355","volume":"11","author":"W Gu","year":"2021","unstructured":"Gu W, Xu C, Li Z, Li ZZ. Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril\u2013valsartan treatment. Cardiovasc Diagn Ther. 2021;11(5):1093\u2013100.","journal-title":"Cardiovasc Diagn Ther."},{"issue":"1","key":"549_CR39","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1038\/s41598-020-63801-2","volume":"10","author":"MV Polito","year":"2020","unstructured":"Polito MV, Silverio A, Rispoli A, Vitulano G, Auria F, De Angelis E, et al. Clinical and echocardiographic benefit of sacubitril\/valsartan in a real-world population with HF with reduced ejection fraction. Sci Rep. 2020;10(1):6665.","journal-title":"Sci Rep"},{"key":"549_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.733475","volume":"12","author":"G Armentaro","year":"2021","unstructured":"Armentaro G, D\u2019Arrigo G, Magurno M, Toscani AF, Condoleo V, Miceli S, et al. Impact of sacubitril\/valsartan on clinical and echocardiographic parameters in heart failure patients with reduced ejection fraction: data from a real life 2-year follow-up study. Front Pharmacol. 2021;12: 733475.","journal-title":"Front Pharmacol"},{"issue":"2","key":"549_CR41","first-page":"125","volume":"36","author":"LW Liu","year":"2020","unstructured":"Liu LW, Wu PC, Chiu MY, Tu PF, Fang CC. Sacubitril\/valsartan improves left ventricular ejection fraction and reverses cardiac remodeling in taiwanese patients with heart failure and reduced ejection fraction. Acta Cardiol Sin. 2020;36(2):125\u201332.","journal-title":"Acta Cardiol Sin."},{"issue":"3","key":"549_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cardfail.2020.12.013","volume":"27","author":"T Martyn","year":"2021","unstructured":"Martyn T, Faulkenberg KD, Albert CL, Il\u2019giovine ZJ, Randhawa VK, Donnellan E, et al. Acute hemodynamic effects of sacubitril-valsartan in heart failure patients receiving intravenous vasodilator and inotropic therapy. J Card Fail. 2021;27(3):368\u201372.","journal-title":"J Card Fail"},{"issue":"4","key":"549_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12435","volume":"36","author":"P Martens","year":"2018","unstructured":"Martens P, Belien H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36(4): e12435.","journal-title":"Cardiovasc Ther"},{"issue":"10","key":"549_CR44","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228\u201334.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"549_CR45","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.1465","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R, et al. Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail. 2019;21(5):588\u201397.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"549_CR46","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/ehf2.12644","volume":"7","author":"C Nordberg Backelin","year":"2020","unstructured":"Nordberg Backelin C, Fu M, Ljungman C. Early experience of sacubitril\u2013valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Fail. 2020;7(3):1049\u201355.","journal-title":"ESC Heart Fail."},{"issue":"11","key":"549_CR47","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.hlc.2020.03.008","volume":"29","author":"A Dashwood","year":"2020","unstructured":"Dashwood A, Vale C, Laher S, Chui F, Rheault H, Gan J, et al. Impact of patient and model of care factors on titration and tolerability of sacubitril\/valsartan: an early Australian real-world experience. Heart Lung Circ. 2020;29(11):1688\u201395.","journal-title":"Heart Lung Circ"},{"issue":"4","key":"549_CR48","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","volume":"74","author":"HY Chang","year":"2019","unstructured":"Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, et al. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372\u201380.","journal-title":"J Cardiol"},{"issue":"9","key":"549_CR49","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ejhf.548","volume":"18","author":"M Senni","year":"2016","unstructured":"Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, et al. Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193\u2013202.","journal-title":"Eur J Heart Fail"},{"key":"549_CR50","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","volume":"69","author":"M\u00c9MK Czeisler","year":"2020","unstructured":"Czeisler M\u00c9MK, Clarke KE, et al. Delay or avoidance of medical care because of COVID-19\u2014related concerns\u2014United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1250\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"549_CR51","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.jacc.2005.08.005","volume":"46","author":"P Agostoni","year":"2005","unstructured":"Agostoni P, Cattadori G, Apostolo A, Contini M, Palermo P, Marenzi G, et al. Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation. J Am Coll Cardiol. 2005;46(9):1779\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"549_CR52","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00392-011-0329-9","volume":"100","author":"F Trinkmann","year":"2011","unstructured":"Trinkmann F, Berger M, Hoffmann U, Borggrefe M, Kaden JJ, Saur J. A comparative evaluation of electrical velocimetry and inert gas rebreathing for the non-invasive assessment of cardiac output. Clin Res Cardiol. 2011;100(10):935\u201343.","journal-title":"Clin Res Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00549-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00549-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T01:05:19Z","timestamp":1667178319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00549-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00549-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"15 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Novartis Pharma GmbH, N\u00fcrnberg, Germany. The sponsor was involved in the design of the study and approved the submission of the present article for publication. Data collection, analysis and interpretation as well as writing of the report were solely performed by the authors of the present article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hanna Fr\u00f6hlich, Norbert Frey, Bent Estler, Mirjam M\u00e4ck, Philipp Schlegel, Jan Beckendorf, Lutz Frankenstein and Tobias T\u00e4ger declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by HF, LF and TT. The first draft of the manuscript was written by HF and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of Heidelberg.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets analysed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}